Atul Mehta1, Uma Ramaswami2, Joseph Muenzer3, Roberto Giugliani4, Kurt Ullrich5, Tanya Collin-Histed6, Zoya Panahloo7, Hartmann Wellhoefer7, Joel Frader8. 1. Department of Haematology, University College, London, UK. atul.mehta1@nhs.net. 2. Department of Haematology, University College, London, UK. 3. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil. 5. International Center for LSD, Hamburg, Germany. 6. International Gaucher Alliance, Dursley, UK. 7. Shire, a Takeda Company, Zurich, Switzerland. 8. Ann & Robert H. Lurie Children's Hospital and Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Abstract
BACKGROUND: Lysosomal storage disorders (LSDs) are rare genetic disorders, with heterogeneous clinical manifestations and severity. Treatment options, such as enzyme replacement therapy (ERT), substrate replacement therapy, and pharmacological chaperone therapy, are available for several LSDs, including Gaucher disease (GD), Fabry disease (FD), and Hunter syndrome (mucopolysaccharidosis type II [MPS II]). However, patients in some countries face challenges accessing treatments owing to limited availability of locally licensed, approved drugs. METHODS: The Takeda LSD Charitable access program aims to meet the needs of individuals with GD, FD or MPS II with the greatest overall likelihood of benefit, in selected countries, through donation of ERT to nonprofit organizations, and support for medical capacity-building as well as family support via independent grants. Long-term aims of the program are to establish sustainable healthcare services delivered by local healthcare providers for patients with rare metabolic diseases. Patients receiving treatment through the program are monitored regularly, and their clinical data and progress are reviewed annually by an independent medical expert committee (MEC). The MEC also selects patients for enrollment completely independent from the sponsoring company. RESULTS: As of 31 August, 2019, 199 patients from 13 countries were enrolled in the program; 142 with GD, 41 with MPS II, and 16 with FD. Physicians reported improvements in clinical condition for 147 (95%) of 155 patients with follow-up data at 1 year. CONCLUSIONS: The response rate for follow-up data at 1 year was high, with data collected for > 90% of patients who received ERT through the program showing clinical improvements in the majority of patients. These findings suggest that the program can benefit selected patients previously unable to access disease-specific treatments. Further innovative solutions and efforts are needed to address the challenges and unmet needs of patients with LSDs and other rare diseases around the world.
BACKGROUND:Lysosomal storage disorders (LSDs) are rare genetic disorders, with heterogeneous clinical manifestations and severity. Treatment options, such as enzyme replacement therapy (ERT), substrate replacement therapy, and pharmacological chaperone therapy, are available for several LSDs, including Gaucher disease (GD), Fabry disease (FD), and Hunter syndrome (mucopolysaccharidosis type II [MPS II]). However, patients in some countries face challenges accessing treatments owing to limited availability of locally licensed, approved drugs. METHODS: The Takeda LSD Charitable access program aims to meet the needs of individuals with GD, FD or MPS II with the greatest overall likelihood of benefit, in selected countries, through donation of ERT to nonprofit organizations, and support for medical capacity-building as well as family support via independent grants. Long-term aims of the program are to establish sustainable healthcare services delivered by local healthcare providers for patients with rare metabolic diseases. Patients receiving treatment through the program are monitored regularly, and their clinical data and progress are reviewed annually by an independent medical expert committee (MEC). The MEC also selects patients for enrollment completely independent from the sponsoring company. RESULTS: As of 31 August, 2019, 199 patients from 13 countries were enrolled in the program; 142 with GD, 41 with MPS II, and 16 with FD. Physicians reported improvements in clinical condition for 147 (95%) of 155 patients with follow-up data at 1 year. CONCLUSIONS: The response rate for follow-up data at 1 year was high, with data collected for > 90% of patients who received ERT through the program showing clinical improvements in the majority of patients. These findings suggest that the program can benefit selected patients previously unable to access disease-specific treatments. Further innovative solutions and efforts are needed to address the challenges and unmet needs of patients with LSDs and other rare diseases around the world.
Entities:
Keywords:
Access; Enzyme replacement therapy; Fabry disease; Gaucher disease; Humanitarian; Hunter syndrome; Low/middle income economies; Lysosomal storage disorders; MPS II
Authors: B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen Journal: Hum Genet Date: 1999 Jul-Aug Impact factor: 4.132
Authors: Ari Zimran; Nadia Belmatoug; Bruno Bembi; Patrick Deegan; Deborah Elstein; Diego Fernandez-Sasso; Pilar Giraldo; Ozlem Goker-Alpan; Heather Lau; Elena Lukina; Zoya Panahloo; Ida Vanessa D Schwartz Journal: Am J Hematol Date: 2017-12-12 Impact factor: 10.047
Authors: Pramod K Mistry; Julie L Batista; Hans C Andersson; Manisha Balwani; Thomas Andrew Burrow; Joel Charrow; Paige Kaplan; Aneal Khan; Priya S Kishnani; Edwin H Kolodny; Barry Rosenbloom; C Ronald Scott; Neal Weinreb Journal: Am J Hematol Date: 2017-07-07 Impact factor: 10.047
Authors: I C Verma; A El-Beshlawy; A Tylki-Szymańska; A Martins; Y-L Duan; T Collin-Histed; M Schoneveld van der Linde; R Mansour; V C Dũng; Pramod K Mistry Journal: Orphanet J Rare Dis Date: 2022-04-04 Impact factor: 4.123